drugset / Trial / NCT04046549
A Study to Evaluate the Safety and Efficacy of Dual Costimulation Blockade With VIB4920 and Belatacept for Prophylaxis of Allograft Rejection in Adults Receiving a Kidney Transplant
NaSingle-groupOpen-labelPrevention
Summary
The purpose of this study is to evaluate the efficacy, safety and tolerability of dual costimulation blockade with VIB4920 in combination of belatacept in adult male or female recipients of a renal allograft from a deceased, living unrelated or human leukocyte antigen (HLA) non-identical living related donor.
Timeline
- Start
- 2019-10-30
- Primary completion
- 2022-07-18
- Completion
- 2023-03-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Belatacept | Protein / enzyme biologic | 5 mg/kg | Intravenous |
| Subject | Dazodalibep | Protein / enzyme biologic | 1500 mg | Intravenous |
| Background | Methylprednisolone | Other / unclassified | 500 mg | Intravenous |
| Background | Prednisone | Other / unclassified | 30 mg | Oral |
| Background | Thymoglobulin | Protein / enzyme biologic | 1.5 mg/kg | Intravenous |
| Background | Thymoglobulin | Protein / enzyme biologic | 3 mg/kg | Intravenous |